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Abstract
Background: The OneDosePlusTM system, based on MOSFET solid-state radiation detectors and a handheld
dosimetry reader, has been used to evaluate intra-fraction movements of patients with breast and prostate cancer.
Methods: An Action Threshold (AT), defined as the maximum acceptable discrepancy between measured dose and
dose calculated with the Treatment Planning System (TPS) (for each field) has been determined from phantom
data. To investigate the sensitivity of the system to direction of the patient movements, fixed displacements have
been simulated in phantom. The AT has been used as an indicator to establish if patients move during a treatment
session, after having verified the set-up with 2D and/or 3D images. Phantom tests have been performed matching
different linear accelerators and two TPSs (TPS1 and TPS2).
Results: The ATs have been found to be very similar (5.0% for TPS1 and 4.5% for TPS2). From statistical data
analysis, the system has been found not sensitive enough to reveal displacements smaller than 1 cm (within two
standard deviations). The ATs applied to in vivo treatments showed that among the twenty five patients treated for
breast cancer, only four of them moved during each measurement session. Splitting data into medial and lateral
field, two patients have been found to move during all these sessions; the others, instead, moved only in the
second part of the treatment. Patients with prostate cancer have behaved better than patients with breast cancer.
Only two out of twenty five moved in each measurement session.
Conclusions: The method described in the paper, easily implemented in the clinical practice, combines all the
advantages of in vivo procedures using the OneDosePlusTM system with the possibility of detecting intra-fraction
patient movements.
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Background
In vivo dosimetry, recommended by various national
and international organizations is a Quality Assurance
tool to measure radiation dose delivered to patients dur-
ing radiotherapy [1-5]. These measurements can be
compared to the planned doses specified by the
oncologist and calculated by the Treatment Planning
System (TPS) for the target and critical organs (e.g. rec-
tum or spinal cord). In this way set-up, calculation, mo-
tion or transcription errors, that may have gone
unnoticed during pre-treatment check, can be recovered.
In the absence of errors, routine in vivo dose measure-
ments document that the treatment was delivered
correctly.
Detectors commonly used for in vivo measurements
are thermoluminescence dosimeters (TLDs), semicon-
ductor diodes and GafchromicW films (International
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Speciality Products, Wayne, NJ) [6,7]. All these devices
have strong and weak points [8]; MOSFET detectors
(Metal Oxide Silicon Field Effect Transistors) are a valid
alternative as in vivo dosimeters [9-13]. They were
designed to replace TLDs having about the same size
and fewer correction factors as compared to diodes.
However, like diodes, they have to be connected to com-
mercial electrometers using cables, which can be dis-
comforting for the patient. Since 2003, the OneDoseTM
and since 2006 the OneDosePlusTM systems (Sicel Tech-
nologies, Morrisville, NC), based on p-type MOSFET
detectors, have been introduced to measure patient dose
in radiotherapy [14-22]. Both systems have all the advan-
tages of MOSFET detectors plus other interesting fea-
tures. The dosimeters are wireless, precalibrated (the
calibration factors for each dosimeter give the relation-
ship between the voltage shift and the amount of
radiation dose) and contain an adhesive backing to be
attached to the patient. In the OneDoseTM system, the
dosimeters for photon and electron beams are the same,
and the user must provide a bolus to achieve the energy
dependent build-up; in the OneDosePlusTM system,
instead, the dosimeters that have to be used on photon
beams, include an integrated build-up cap to achieve
charged particle equilibrium conditions. These features,
together with the possibility to create a permanent rec-
ord of the dose, make this system particularly suitable
for in vivo dosimetry in treatment techniques such as
brachytherapy, total body irradiation and 3-D conformal
radiation therapy. Technical aspects of the design and
tests of the performance of the OneDoseTM system in
measuring dose per monitor unit in different conditions
using the AAPM TG-21 protocol [23] have been
described in the literature [15].
In in vivo dosimetry all those factors which influence
dose deposition, especially when very high doses of radi-
ation are prescribed, have to be taken into account.
However, all these factors may not all influence simul-
taneously the delivery of a specific dose. In addition,
even the best in vivo dosimeter cannot distinguish the
causes of a dose discrepancy, but it records only their
total effect. All the possible error sources need to be
investigated to provide an accurate estimation of the
delivered dose. The aim of this work is to use the One-
DosePlusTM system to investigate the dosimetric effect
of the movement of patients in selected tumor sites
(breast and prostate) during radiotherapy treatments.
Methods
The OneDosePlusTM detector system comprises a single
p-type wireless MOSFET detector and a handheld reader.
The manufacturer provided one reader and individual
dosimeters from the same manufacturing lot (Figure 1).
The MOSFET detectors have physical dimensions of
3.5 x 0.7 cm2 with an active area of 300 x 50 μm2
situated in the center of the exit surface build-up cap.
They are provided with an adhesive strip to be attached to
the patient’s skin. The build-up cap, instead, is a tin disk
of 1.194 ± 0.008 mm thickness (equivalent to 1.4 cm in
water) and 5.004 ± 0.254 mm diameter, flash coated with
gold to prevent oxidation. A green dot specifies the active
area. The dose measured by the detector is the maximum
of the Percentage Depth Dose (PDD), and is referred to
the corresponding maximum depth, dmax in water. For a 6
MV beam, the measurements correspond to the dose at
dmax equal to1.4 cm. For all the other energies, correction
factors relate the MOSFET readings to the corresponding
doses at dmax.
The manufacturer system specifications [14] are: dose
range between 0 and 500 cGy, with an accuracy of ±5%
(within 2 Standard Deviation, 2SD) and ±2 cGy for doses
below 30 cGy; energy range from 60Co to 18 MV; SSD
from 80 to 120 cm and dose linearity from 2 to 400 cGy;
no angular dependence (limited to ±30° incident beam
angle) and no temperature dependence (accuracy main-
tained to up to ±5°C variation during zeroing and post-
dose reading). The dosimetric system is factory calibrated
with a 60Co beam in full build-up conditions and in the fol-
lowing settings (hereafter named “standard conditions”):
6MV photon beam, SSD = 100 cm, 10 cm x 10 cm field
size, 300 MU/min dose rate and no wedge. To relate
MOSFET readout to dose in conditions other than stand-
ard, the manufacturer provides correction factors. These
factors are a function of treatment specific parameters such
as energy, SSD, field size, wedge filter characteristics and
dose rate (energy/modality corrective factors). They are
Figure 1 OneDosePlusTM system. The system comprises single p-
type wireless MOSFET detectors and a handheld reader.
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written onto each dosimeter and specified in a calibration
sheet (Lot Calibration). Calibration factors are determined
for each single dosimeter while the correction factors are
determined from a random sampling of detectors and ap-
plied to the entire lot. After irradiation the dose is mea-
sured by inserting the dosimeter in the handheld
reader. If treatment specific parameters are entered before
irradiation, the reader shows the corrected dose, otherwise,
standard conditions are assumed and correction factors can
later be applied by hand calculation. Optimum results are
obtained if the post-dose reading is taken 2.5 minutes after
irradiation to avoid fading.
Prior to implementation for in vivo dosimetry, the One-
DosePlusTM system has been thoroughly investigated in
two phantoms, a thorax anthropomorphic phantom and a
slab phantom, to establish a baseline of dose discrepancy
with respect to our TPS. This part of the study was aimed
at establishing an Action Threshold (AT) [5,24], defined
as the maximum accepted discrepancy between the dose
measured with the detector and the dose calculated with
the TPS for a single field (in our procedure only one field
at a time is verified). A single AT has been established,
one specific for breast and one for prostate treatments,
from the analysis of the tests in phantoms, and it has been
used as an indicator of the correctness of breast and pros-
tate treatments themselves. Two TPSs were used: the
Precise Plan (Elekta, Crawley, United Kingdom) for breast
and prostate treatments and Pinnacle3 version 8.0 m
(Philips Medical System, Andover, MA), for prostate treat-
ments only. Measurements were performed on two differ-
ent linear accelerators: an Elekta Precise (Elekta, Crawley,
United Kingdom), with nominal X-ray energies of 6 and 15
MV and with Precise Plan as TPS, and an Elekta Synergy S
(Elekta, Crawley, United Kingdom), with nominal energies
of 6 and 18 MV and with Pinnacle3 as TPS, respectively.
Consequently, the AT has been determined in each com-
bination accelerator + TPS. The measurements were per-
formed without inserting the manufacturer’s corrective
factors into the reader before treatment but correcting the
readings after the treatment using the formulas in the lot
calibration. This solution was chosen to minimize the
duration of the procedure before treatment.
Initially the patient set-up was verified and, if needed,
corrected using a 2D (breast and some prostate patients)
or a 3D (only prostate patients) verification system. In
the 2D verification procedure, some structures were out-
lined by the Radiation Oncologist both on the Digitally
Reconstructed Radiographs (DRRs) and the portal
images acquired by the IVIEWGT (Elekta, Crawley, United
Kingdom). The displacements were evaluated after the soft-
ware matched the outlines in both images. The set-up was
corrected if the displacements exceeded 2 mm. In the 3D
verification procedure, instead, the registration between the
planning CT and the pre-treatment Cone Beam CT
(CBCT) scan, was performed automatically by the
XVI software (Elekta, Crawley, United Kingdom) using a
3D chamfer matching algorithm. The set-up was corrected
if the calculated displacements exceeded 2 mm. Only trans-
lational set-up errors were considered and corrected online,
as our treatment couch cannot perform pitch and roll rota-
tions. However, the patient was always repositioned when-
ever calculated rotational set-up errors were 1° or more.
Two MOSFETs were used for each patient: one for the
first and one for the last field of the treatment session (in
our centre prostate treatments is delivered with six fields
while breast treatments with two tangential opposing
wedged fields). If the discrepancy between the measured
dose, corrected with the appropriate corrective factors,
and the dose calculated with the TPS was above the AT
value, an intra-fraction motion error was assumed to have
occurred.
A. Phantom tests and AT calculation
To determine the AT for breast treatments, a thorax an-
thropomorphic phantom (model RS-111, RSD Radiology
Support Devices, Inc. USA) has been used. A typical
breast tangential medial wedged field (6 MV photons,
asymmetrical field size, SSD 92 cm, 30° wedge, 100° col-
limator angle and 305° gantry angle) has been simulated
with the Precise Plan as TPS, having energy, collimator
angle, gantry angle, SSD, field size and wedge similar to
those used for patient’s treatments. Only the tangential
medial wedged field has been considered as both tangen-
tial fields (medial and lateral) are equal and opposite
with the isocenter placed at the midpoint of the target in
the longitudinal direction. The field was strongly asym-
metrical in the wedge direction as in the majority of
breast treatments. For prostate treatments, we have used
a field equivalent square of 7.5 cc, with a SSD of 88 cm,
an energy of 18 MV and a collimator angle of 0°. Only
the 90° gantry field (rotated to 0° gantry) on a 30x30x20
cm3 RW3 slab phantom (ρ=1.045 g/cm3) has been simu-
lated (90° and 270° gantry angles are equal and opposite
with the isocenter placed at the midpoint of the target in
all directions). Also in this case, the chosen set-up has
been as much as possible similar to that of the majority
of prostate treatments.
For each field, and for each measurement, which was
repeated ten times, we defined the dose discrepancy, Δi, as
the percentage difference between the dose measured with
the dosimetric system, Di, and Dc, the reference dose
calculated with the TPS in the same phantom set-up:
Δi ¼ Di  DcDc ð1Þ
Finally, we calculated the mean dose discrepancy, indi-
cated with Δ, and its standard deviation (Δ±SD (Δ)). Δ
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was used for each patient in each measurement session,
to calculate the difference between the dose actually
measured at the surface patient projection of the isocen-
ter, and that calculated at the isocenter using the
corresponding TPS, during in vivo check dosimetry. The
AT, instead, was calculated as twice the standard devi-
ation of the ten differences (within the confidence inter-
val of 95%). Other plausible combinations of SSD, gantry
angle, field size and wedge angle have been randomly
considered and the differences with the corresponding
calculated doses evaluated. This set of measurements
has led to an additional error of 0.5% to add to the AT
previously calculated. A further 0.5% has been added to
take into account the MOSFET positioning error due to
difficulty to exactly place the detector at the surface pro-
jection of the isocenter on the phantom, or on the pa-
tient. In our tests, the SD was considered as the random
error; while Δ as the systematic error. The latter has not
been taken into account for in vivo evaluations since it
was found to be negligible.
To investigate the most likely directions of the intra-
fraction patient movements, five MOSFETs were placed
at fixed displacements with respect to the beam central
axis (surface projection of the isocenter on the phan-
tom), considered as the reference point, and irradiated
(we carried out one displacement at a time). We wanted
to determine not only the direction of the displacements
during each treatment session but also if the system was
actually able to detect them. We first considered 3 mm
(the displacement that does not affect dose target distri-
bution) in all 3D directions, then 1 cm. In breast treat-
ments and towards the wedge toe, the displacement
performed was 0.7 cm, since 1 cm displacement would
lead to the field edge. The directions of displacements
were (looking towards the gantry): couch to the right,
couch to the left, couch to gun, couch to target, couch
up and down. The average values for each direction and
displacement length, have been put in comparison to the
reference. A statistical analysis of these data has been
performed to establish the sensitivity of the system in
detecting the displacements.
B. In vivo measurements
Twenty five patients with breast cancer and twenty five
patients with prostate cancer were considered for this
study. Each dosimeter was attached to the patient’s skin
with its build-up cap area at the surface projection of
the isocenter and as perpendicular as possible to the
beam central axis. The approximate perpendicularity
(within ±30°) between the beam axis and MOSFET sur-
face was verified by the Radiation Technologist with a
rigid sheet of paper placed on the MOSFET surface. The
patients with breast cancer had their treatments planned
with the Precise Plan TPS and were irradiated with the
Elekta Precise accelerator. Patients with prostate cancer,
were split into two groups: the first group included 10
patients treated with the same accelerator, the same TPS
and the same 2D verification system as the breast
patients; the second group, instead, included 15 patients
whose treatments were planned with Pinnacle3 and who
were irradiated with the Elekta Synergy S. In both TPSs,
the doses were calculated isolating the contribution of
the field which was to be measured with the MOSFET.
The calculated dose value was taken at the depth dmax
along the central ray passing through the isocenter.
These doses were compared with the measurements
obtained with the dosimetric system, after correction by
energy/modality corrective factors. For each patient, the
measurements were performed, once a week, using one
MOSFET for the selected field of the treatment plan.
In patients with breast cancer, both medial and lateral
fields were monitored. Figure 2 shows the MOSFET de-
tector positioned at the surface projection of the isocen-
ter for the lateral field; the approximate perpendicular
beam incidence is also visible. To correct the set-up, the
IVIEWGT verification system has been used before each
irradiation. A commercial breast board (AKTINA Med-
ical) was used as immobilization device. The dose frac-
tionation schedule was 4400 cGy delivered to the
isocenter in 16 fractions (275 cGy/fr) with 6 MV
photons. One detector was irradiated for each field, once
a week. This amounted to four detectors per field at the
end of the treatment course. The eight dose values mea-
sured along the entire treatment were averaged and the
resulting value together with its standard deviation, has
been reported and compared to the dose calculated with
the TPS.
In patients with prostate cancer, the treatment field at
90°gantry angle was first verified, then the field at 270°,
Figure 2 Breast treatment. MOSFET detector positioned at the
surface projection of the isocenter on a patient treated for breast
cancer (lateral field).
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which was the last field delivered in each treatment
session (the treatment being delivered using six fields at
90°, 45°, 135°, 225°, 315°, 270°) (Figure 3). The treatment
was delivered in 33 sessions over 6 weeks with a total
dose of 6600 cGy (200 cGy/fr at the isocenter). The
energy used was 15 MV for the Elekta Precise and 18
MV for the Elekta Synergy S. A home-made foot block and
a pillow under the head were used as immobilization de-
vice. Twelve dosimeters (six for 90° gantry angle and six for
270° gantry angle) for each patient have been irradiated at
the end of the treatment course. The dosimeters were
placed on the hip as perpendicular as possible to the beam
central axis. The twelve dose values measured along the en-
tire treatment were averaged and the result, together with
its standard deviation, has been reported and compared to
the reference dose calculated with the corresponding TPS.
The attenuation of the MOSFET detectors was not con-
sidered in treatment planning since it was measured and
found negligible according to our in vivo procedure. Writ-
ten informed consent was obtained from the patient for
publication of this report and any accompanying images.
Results
A. Phantom tests and AT calculation
For the tangential medial wedged field, the average dose
of ten repeated measurements on the Elekta Precise was
(379.0 ± 5.3) cGy, while the corresponding dose calcu-
lated with Precise Plan TPS (TPS1) was 379.7 cGy. The
SD of the ten dose differences was about 1.5%. The same
result has been obtained for the prostate treatment, using
the same linear accelerator and TPS (TPS1) of the breast
treatment (not reported). Therefore, AT1 = 5.0%. For pros-
tate treatments and for the Elekta Synergy S the average
dose of ten repeated measurements was (194.4 ± 2.3) cGy,
while the corresponding dose calculated with Pinnacle3
TPS (TPS2), was 193.5 cGy. The SD was 1.2%. Making the
same considerations above reported, the overall result for
AT2 was ± 4.5%.
The results of the displacements made in the phan-
toms with respect to the reference point, are reported in
Additional file 1: Table S1 and Additional file 2: Table S2
for breast and prostate treatments, respectively. For each
displacement, we have assumed that the values mea-
sured followed the Student’s t distribution with ν = 5
degrees of freedom. From the statistical analysis of the
data in Additional file 1: Table S1, we have found that,
for each displacement, the differences between the average
values and the corresponding reference, are statistically sig-
nificant only in three cases (p value <0.005). The system,
therefore, is sensitive to displacements of: 1) 0.7 cm to-
wards the toe of the wedged field (named s1), which corre-
sponds to a displacement towards the penumbra region
(the worse value); 2) 1 cm toward the heel of the wedged
field, with the couch to the left (named s2) and 3) 1 cm
with the couch up (named s3). The latter is the displace-
ment that can be due to the respiratory acts of the patient
where a large SSD variation can be observed. Shaded rows
mark these displacements. The maximum discrepancies
found were −6.0%, -4.9% and +3.5% for s1, s2 and s3, re-
spectively. These values were smaller than AT1 (±5.0%), ex-
cept s1. If we consider 2 SD, the new value of s1 becomes
smaller than AT1. Therefore, the system is not able to
detect displacements smaller than 1 cm.
For prostate treatments, the corresponding statistical
analysis of data reported in Additional file 2: Table S2,
has shown that the differences between the reference
dose value and the average dose for each displacement,
are statistically significant in two cases (197.9 ± 2.1 cGy
and 190.3 ± 1.9 cGy, respectively) which corresponds to
displacements of the couch up and down. Shaded rows
mark these displacements. The maximum discrepancy
found was −2.6% and +3.3%, both smaller than AT2.
Also in this case, the system can detect only displace-
ment not smaller than 1 cm. For prostate data and for
TPS1 + Elekta Precise accelerator, similar results have
been obtained (not shown).
B. In vivo measurements
Figure 4 shows the data for twenty five patients with breast
cancer and TPS1. The mean discrepancy was −1.4% with a
SD of 3.8%. These values were averaged on both fields
(medial and lateral) and along the entire treatment. To
investigate if the patients moved during both fields or only
during the last field of the treatment session, data were also
split into medial and lateral field only. Figures 5 and 6 show
the average discrepancy for the medial and the lateral field,
respectively. In these plots, the mean discrepancy
was −2.2% with a SD of 3.0%, and 0.9% with a SD of 5.1%
for the medial and the lateral field, respectively. The lateral
Figure 3 Prostate treatment. MOSFET detector positioned at the
surface projection of the isocenter on a patient treated for prostate
cancer (90° field).
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field show a wider data dispersion with respect to the
medial one. In the figures, red dots mark the Δ values
exceeding AT1.
In Figure 7, data for prostate patients using TPS1 and
a 2D verification system, are shown. The discrepancies
reported are lower than those observed in breast
patients, with a mean discrepancy of −1.0% and a SD of
1.9%. It has to be pointed out that only average values
have been reported. Only for two patients and only for
one treatment session, the discrepancy exceeded AT1.
This happened in the first treatment session and never
again.
In Figure 8, data for prostate patients using TPS2 and
a 3D-CBCT verification system, are displayed. The mean
discrepancy was −1.6% with a SD of 3.0%. Red dots mark
the patients whose Δ values have been found to exceed
AT2 in each treatment session. The first one, had a Δ value
negative, indicating a displacement towards the source. The
other, had a positive discrepancy indicating that the patient
moves away from the source. A wider data dispersion, how-
ever, can be observed in the patients treated with Elekta
Synergy S (SD=3.0%) compared to those treated with
Elekta Precise (SD=1.9%). In the statistical analysis of
patients treated with Elekta Synergy S, except for patients #
1 and 14 (that can be considered as “outliers”), the data dis-
persion is similar (SD=2.0%) to that obtained for patients
treated with Elekta Precise (SD=1.9%), with a similar mean
discrepancy too (−0.8% compared to −1.0%). Finally, it can
be observed that, again except for patients # 1 and 14, the
data dispersion for each patient is less wide than that
obtained in patients treated with Elekta Precise, shown in
Figure 7.
Discussion
The AT values calculated using data from phantom tests
for two different TPSs, were found to be very similar, ±5.0%
for TPS1 and ±4.4% for TPS2, and of the same order
of the magnitude of the intrinsic system uncertainty
(2SD = ±5.0%). This is due to the fact that SD1 is
not so much different from SD2, even if SD2 has been
determined from TPS2 (Pinnacle3) which is more accurate
than TPS1 (Precise Plan) in calculating doses (SD1 is 1.5%
for TPS1, and SD2 is 1.2% for TPS2). This means that the
system is reproducible with respect to each TPS. This result
Figure 4 Breast treatment with the Elekta Precise. Average discrepancy using TPS1 and a 2D verification system, for both medial and lateral
fields along the entire treatment course.
Figure 5 Breast treatment with the Elekta Precise. Average discrepancy using TPS1 and a 2D verification system, for the medial field along
the entire treatment course.
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is similar to those found in other institutions [5,24] using
other measurement devices like different MOSFET or
diode based dosimeters.
Among the twenty five patients treated for breast
cancer, only in four of them Δ was larger than AT1 in
each measurement session over a treatment lasting two
weeks and half. Other six patients, randomly moved
during the treatment. After the first session, we told the
patient not to move during the treatment but the results
of the measurements of the subsequent weeks reported in
our figures, show that they didn’t follow our instructions or,
more likely, the position of treatment was too hard to keep
for the long treatment time (it lasted about 10 minutes), so
they probably relaxed their arms causing a shift of the point
in which the dosimeter was placed. This shift could have
caused a change of the measured dose due to the gradient
across the wedge and also across the penumbra of the field.
The discrepancies larger that the corresponding ATs,
have a general negative trend. However, some of them have
positive values indicating that either the corresponding
fields are different from that simulated in the phantom
study (likely in patient # 12, where the length of the field
was larger than 1 cm in the toe direction of the wedge); or
that an abdomen expansion due to a deeper than average
inspiration had happened (likely in the patient # 24, who
had a discrepancy value larger then AT1, both in medial
and lateral fields).
In vivo results for patients with prostate cancer have
shown better results compared to patients with breast
cancer. This result indicates that this kind of treatment
is more reproducible, also due to the immobilization
system which makes movements difficult. Patients # 1
and 14 have been positioned with a 3D-CBCT scanner,
known to be more accurate than a 2D system [25-27].
This clearly shows that even if the patient is positioned
using the best and the most accurate verification system,
motion during the treatment session causes a loss of ac-
curacy in the treatment. However, the general trend of a
reduced data dispersion, calculated along the entire
treatment, for patients treated with Elekta Synergy S
compared to those calculated with Elekta Precise, indi-
cate that if patients don’t move and they are positioned
Figure 6 Breast treatment with the Elekta Precise. Average discrepancy using TPS1 and a 2D verification system, for the lateral field along the
entire treatment course.
Figure 7 Prostate treatment with the Elekta Precise. Average discrepancy using TPS1 and a 2D verification system along the entire treatment
course.
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using the best 3D-CBCT scanner, treatment accuracy
improves.
In Image-Guided Radiation Therapy (IGRT) and Inten-
sity Modulated Radiation Therapy (IMRT) techniques, the
time of patient setup and treatment delivery has increased,
together with the need to monitor and manage patient
motion during treatment. There are different systems based
on new technologies to monitor internal tumor motion, pa-
tient motion or both during treatment. As concerns exter-
nal motion detection and measurement, Infrared (IR)
cameras which use infrared external markers [28,29],
spirometry [30], electromagnetic positioning systems [31]
or in-house devices [32,33] have been used to monitor
patient’s and respiratory motion. The accuracy declared by
the manufacturers in detecting displacements of the chest
wall is about 1 mm for the commercial devices, and
increases to 0.5 - 1.25 cm in the in-house systems. Some of
these systems focus on detecting chest wall motion to
predict tumor motion, the commercial systems being, in
addition, quite expensive. The external displacements can
however differ from internal tumor displacements up to
about 2 cm, as reported by some authors [34-36]. Tumor
motion, can be directly measured by surgically implanting
fiducial markers into the tumor. The movements of these
markers can be then tracked using fluoroscopy [37] or
other techniques [38]. The use of internal markers, suffers
from high level of morbidity (the clips can migrate) and,
when fluoroscopy is used to track the markers, additional
dose is delivered to the patient [35,39]. All these systems
concentrate in extracting information about intra-fraction
organ motion but they not consider the dose that the target
really receives. In a recent publication [32], the authors use
a new 4D in vivo dosimetry tool (based on MOSFET dosi-
meters combined to an electromagnetic positioning sensor)
to simultaneously measure real time dose delivery to the
center of the field and surface lung motion. Our method-
ology is based on the idea of using only “in vivo” dosimetric
information to detect intra-fraction patient movements
during treatment. It is very simple to implement, can be
used in every type of treatment, it is not expensive and can
1) give both dose measurements and intra-fraction patient
movements; 2) use in vivo dose measurements to give in-
formation about the direction of target movements and 3)
estimate the dose received from the isocenter (inside the
target) from the dose measured in two opposing fields. The
main limitations, however, are that the system can only
monitor external motion and that the assessment of the
intra-fraction motion cannot be made on-line in a continu-
ous fashion but only at the end of the treatment session.
The accuracy of the method was found to be of 1 cm
which means that displacements larger than 1 cm can be
detected. However, this depends on whether a displacement
produces a significant difference between measured and
calculated dose, which in turn depends on the kind of treat-
ment and treatment site. Our work was focused on 3D con-
formal treatments; due to extreme sensitivity of the system
to rapid dose variations, we believe that the accuracy can
be improved when monitoring movements in patients trea-
ted with IMRT.
Conclusion
The dosimetric performance of the OneDosePlusTM
system for in vivo dosimetry has been studied with
respect to two different TPSs. The ATs established in
phantom tests have been found to be of the same order
of magnitude and independent from the TPS used. This
procedure applied to patients after correction of the set-
up errors, has allowed the identification of large random
movements in some patients, which resulted to be more
pronounced in breast than in prostate treatments. In
addition, the results obtained indicate that these move-
ments are not dependent on the kind of the verification
system (2D or 3D) used to correct the set-up. The
method decribed in the paper, easily implemented in
clinical practice, combines all the advantages of the One-
DosePlusTM system, such as the small size of the
dosimeter, absence of cables, instant read-out, permanent
storage of dose and ease of use, with the possibility of
detecting intra-fraction patient movements.
Figure 8 Prostate treatment with the Elekta Synergy S. Average discrepancy using TPS2 and a 3D-CBCT verification system along the entire
treatment course.
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